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Efficacy and safety of abrocitinib in adults and adolescents 
with moderate-to-severe atopic dermatitis (JADE MONO-1): 
a multicentre, double-blind, randomised, placebo-controlled, 
phase 3 clinical trial
Eric L Simpson, Rodney Sinclair, Seth Forman, Andreas Wollenberg, Roland Aschoff, Michael Cork, Thomas Bieber, Jacob P Thyssen, Gil Yosipovitch, 
Carsten Flohr, Nina Magnolo, Catherine Maari, Claire Feeney, Pinaki Biswas, Svitlana Tatulych, Hernan Valdez, Ricardo Rojo
Summary
Background Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with 
moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib 
monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis.
Methods In this multicentre, double-blind, randomised phase 3 trial (JADE MONO-1), patients (aged ≥12 years) with 
moderate-to-severe atopic dermatitis (Investigator Global Assessment score ≥3, Eczema Area and Severity Index [EASI] 
score ≥16, percentage of body surface area affected ≥10%, and Peak Pruritus Numerical Rating Scale [PP-NRS] score 
≥4) with a bodyweight of 40 kg or more, were enrolled at 69 sites in Australia, Canada, Europe, and the USA. Patients 
were randomly assigned (2:2:1) to oral abrocitinib 100 mg, abrocitinib 200 mg, or placebo once daily for 12 weeks. 
Randomisation was done using an interactive response technology system, stratified by baseline disease severity and 
age. Patients, investigators, and the funder of the study were masked to study treatment. The coprimary endpoints 
were the proportion of patients who had achieved an Investigator Global Assessment response (score of 0 [clear] or 
1 [almost clear] with a ≥2-grade improvement from baseline), and the proportion of patients who achieved at least a 
75% improvement in EASI score from baseline (EASI-75) score, both assessed at week 12. Efficacy was assessed in the 
full analysis set, which included all randomised patients who received at least one dose of study medication. Safety was 
assessed in all randomised patients. This study is registered with ClinicalTrials.gov, NCT03349060.
Findings Between Dec 7, 2017, and March 26, 2019, 387 patients were enrolled: 156 were assigned to abrocitinib 100 mg, 
154 to abrocitinib 200 mg, and 77 to placebo. All enrolled patients received at least one dose of study treatment and 
thus were evaluable for 12-week efficacy. Of the patients with available data for the coprimary endpoints at week 12 [A: 
edit ok?],  the proportion of patients who had achieved an Investigator Global Assessment response was significantly 
higher in the abrocitinib 100 mg group than in the placebo group (37 [24%] of 156 patients vs six [8%] of 76 patients; 
p=0·0037) and in the abrocitinib 200 mg group compared with the placebo group (67 [44%] of 153 patients vs vs 
six [8%] of 76 patients; p<0·0001). Of the patients with available data for the coprimary endpoints at week 12 [A: edit 
ok?], compared with the placebo group, the proportion of patients who had achieved an EASI-75 response was 
significantly higher in the abrocitinib 100 mg group (62 [40%] of 156 patients vs nine [12%] of 76 patients; p<0·0001) 
and abrocitinib 200 mg group (96 [63%] of 153 patients vs nine [12%] of 76 patients; p<0·0001). Adverse events were 
reported in 108 (69%) of 156 patients in the abrocitinib 100 mg group, 120 (78%) of 154 patients in the abrocitinib 
200 mg group, and 44 (57%) of 77 patients in the placebo group. Serious adverse events were reported in five (3%) of 
156 patients in the abrocitinib 100 mg group, five (3%) of 154 patients in the abrocitinib 200 mg group, and three (4%) 
of 77 patients in the placebo group. No treatment-related deaths were reported.
Interpretation Monotherapy with oral abrocitinib once daily was effective and well tolerated in adolescents and adults 
with moderate-to-severe atopic dermatitis.
Funding Pfizer.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
Atopic dermatitis is a chronic and relapsing inflammatory 
skin condition with a complex pathophysiology that 
involves the interplay of impaired skin barrier function, 
immune dysregulation, genetic susceptibility, and envi­
ronmental factors.1 Atopic dermatitis is characterised by 
intense pruritus.2 Although estimates vary widely, atopic 
dermatitis has been reported to affect up to 20% of 
children and adolescents and up to 10% of adults, and is 
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associated with considerable impairment in quality of 
life, sleep, depression, anxiety, and work absenteesm.3–6
Management of moderate­to­severe atopic dermatitis 
often necessitates systemic therapy; however, few options 
are available and, of those that are available, most are not 
approved for atopic dermatitis and can be limited by their 
risk of adverse effects. Systemic corticosteroids might 
offer higher efficacy than topical treatments in patients 
with moderate­to­severe atopic dermatitis, but their effect 
is often accompanied with short­term and long­term 
side­effects, and long­term use is not recommended.7 
Other treatment options include immunosuppressive 
drugs, such as ciclosporin, methotrexate, azathioprine, 
and mycophenolate mofetil. None of these drugs are 
approved for the treatment of moderate­to­severe atopic 
dermatitis in the USA or Europe; however, ciclosporin is 
licensed in many European countries for the treatment 
of severe atopic dermatitis. These drugs have been 
reported to have a broad adverse event profile and poor 
tolerability, especially when used long­term.7
Dupilumab is a fully human monoclonal immuno­
globulin G4 antibody that binds to the shared α chain of 
interleukin­4 (IL­4) and IL­13 receptors, partly restricting 
T­helper­2 (Th2) cell­driven inflammatory acti vity.8,9 
Dupilumab is approved by the US Food and Drug 
Administration and European Medicines Agency for the 
treatment of adolescents and adults with moderate­to­
severe atopic dermatitis. Some patients do not respond 
sufficiently to dupilumab, whereas others lose response 
over time10 (potentially as a result of drug­neutralising 
antibodies).11 In clinical trials, conjunctivitis was recorded 
as an adverse event with dupilumab treatment, which 
can lead to treatment cessation and the need for 
ophthalmological care.12,13 Furthermore, dupilumab is 
administered subcutaneously, which could prevent use in 
patients who are unwilling to receive injections.14 Hence, a 
need exists for an efficacious oral treatment with a 
favourable benefit­risk profile for patients with moderate­
to­severe atopic dermatitis. The Janus kinase (JAK) family 
are a group of cytoplasmic tyrosine kinases (JAK1, 
JAK2, JAK3, and tyrosine kinase 2), which bind cytokine 
receptor intra cellular chains to form functional signalling 
complexes. JAKs associate with receptor chains, and on 
receptor activation dimerise (as homodimers or hetero­
dimers) to form receptor com plexes. Various cytokines 
relevant to the pathophysiology of atopic dermatitis, 
including IL­4, IL­13, IL­22, IL­31, and thymic stromal 
lymphopoietin15–17 activate JAK1­containing heterodimeric 
receptors, thereby mediating Th2 cell differentiation and 
itch via downstream effects. JAK2 forms homodimeric 
receptor complexes involved in hematopoiesis.18 There­
fore, selective inhibition of JAK1 is a desirable target to 
modulate a broad range of cytokines involved in the 
pathogenesis of atopic dermatitis while avoiding the 
undesirable effects of JAK2 inhibition, such as neutropenia 
and anaemia.
Abrocitinib (formerly known as PF­04965842) is an oral, 
JAK1 selective inhibitor under investigation for the treat­
ment of atopic dermatitis. Monotherapy with oral 
abrocitinib 100 mg or 200 mg once daily was effective and 
Research in context
Evidence before this study
Atopic dermatitis is a chronic and recurrent inflammatory skin 
condition characterised by intense pruritus. At present, the 
available systemic treatments for patients with moderate-to-
severe atopic dermatitis are limited by their short-term and 
long-term side-effects. Dupilumab is a subcutaneous systemic 
drug recently approved in adolescents and adults with 
moderate-to-severe atopic dermatitis. Not all patients with 
moderate-to-severe atopic dermatitis respond to dupilumab, 
and treatment is associated with a risk of conjunctivitis. 
Furthermore, the use of dupilumab is limited in patients who are 
unwilling to receive injections. Hence, there is a need for an 
efficacious, oral treatment with a favourable benefit–risk profile 
for patients with moderate-to-severe atopic dermatitis. 
We searched PubMed on June 4, 2020, for studies published in 
English between 2010 and 2019, using the search terms “atopic 
dermatitis” or “eczema” AND “treatment” or “moderate to 
severe” or “moderate-to-severe” AND “phase 3” or “phase III”. 
Our search yielded nine clinical trials of systemic therapy.
Added value of this study
This phase 3 trial investigated the efficacy and safety of oral 
abrocitinib in adolescents and adults with moderate-to-severe 
atopic dermatitis. Abrocitinib 200 mg and 100 mg significantly 
improved signs and symptoms of moderate-to-severe atopic 
dermatitis compared with placebo. At week 12, the proportion 
of patients in the abrocitinib 100 mg and 200 mg groups who 
had achieved an Investigator Global Assessment response and 
75% improvement in Eczema Area and Severity Index score 
was significantly higher than in the placebo group. 
Improvements in pruritus were observed at the first post-
baseline assessment. Abrocitinib had a favourable safety 
profile in this 12-week study, and no cases of venous 
thromboembolism, malignancy, major adverse cardiovascular 
events, or deaths were observed.
Implications of all the available evidence
Oral abrocitinib 100 mg or 200 mg monotherapy 
administered once daily was effective in patients with 
moderate-to-severe atopic dermatitis with a favourable safety 
profile. Our results suggest that abrocitinib was well tolerated 
and could present an efficacious oral systemic drug for the 
treatment of moderate-to-severe atopic dermatitis in patients 
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well tolerated in a dose­ranging phase 2b study in adults 
with moderate­to­severe atopic dermatitis.19 At week 12, the 
proportion of patients who had achieved the primary 
endpoint of Investigator Global Assessment response 
(0 [clear] or 1 [almost clear] with ≥2­grade improvement 
from baseline) was 43·8% for the 200 mg dose and 29·6% 
for the 100 mg dose compared with 5·8% for placebo 
(p<0·05 for both). Additionally, reductions in Eczema Area 
and Severity Index (EASI) score20 and pruritus numeric 
rating scale were observed in the abrocitinib 200 mg and 
100 mg groups. Abrocitinib had a favourable safety profile, 
with most adverse events being mild and considered 
unrelated to treatment. On the basis of the positive benefit 
to risk ratio of the abrocitinib 200 mg and 100 mg doses, a 
phase 3 trial was designed to assess these doses further.
Here, we report results from the phase 3 trial JADE 
MONO­1, which investigated monotherapy with oral 
abrocitinib in adolescent and adult patients with 
moderate­to­severe atopic dermatitis.
Methods
Study design and participants
JADE MONO­1 was a multicentre, double­blind, ran­
domised, placebo­controlled, phase 3 trial done at 
69 hospitals and clinics in Australia, Canada, Europe, and 
the USA. Eligible patients were aged 12 years or older, 
with a bodyweight of 40 kg or more. Adolescent patients 
aged younger than 18 years were eligible on a country­by­
country basis as approved by the country or regulatory 
health authority. All eligible patients had a confirmed 
diagnosis of atopic dermatitis for at least 1 year before 
randomisation (according to Hanifin and Rajka diag­
nostic criteria21); had moderate­to­severe atopic dermatitis 
(Investigator Global Assessment score ≥3, EASI score 
≥16, percentage of body surface area affected ≥10%, and 
Peak Pruritus Numerical Rating Scale [PP­NRS] score ≥4) 
at the baseline visit. The PP­NRS score used with the 
permission of Regeneron Pharmaceuticals (Tarrytown, 
NY, USA) and Sanofi SA (Paris, France)22 [A: Moved info 
about permission here, so that the information in 
parantheses is clearer for readers, ok?]. Eligible patients 
also had a documented recent history (in the 6 months 
before screening) of inadequate response to treatment 
with topical cortico steroids or topical calcineurin 
inhibitors given for at least 4 weeks, or were patients for 
whom topical treatments were otherwise medically 
inadvisable, or required systemic therapies to control 
their disease. Patients with acute or chronic medical or 
psychiatric conditions (including active suicidal ideation 
or behaviour) or laboratory abnor malities in the past year 
Figure 1: Trial profile
16 discontinued
    7 adverse event
    4 no longer willing to 
participate
     2 insufficient clinical response
     2 other
     1 protocol violation
21 discontinued
    9 adverse event
    5 no longer willing to
        participate
     4 other
     2 protocol violation
     1 insufficient clinical response
17 discontinued
    9 adverse event
    3 no longer willing to
        participate
      3 other
     2 protocol violation
61 completed study treatment 135 completed study treatment 137 completed study treatment
77 included in full analysis set 156 included in full analysis set 154 included in full analysis set
77 assigned to receive placebo 
77 received ≥1 dose of study 
treatment
156 received ≥1 dose of study 
         treatment
154 received ≥1 dose of study 
         treatment
156 assigned to receive 
         abrocitinib 100 mg
154 assigned to receive 
         abrocitinib 200 mg
553 participants assessed for eligibility 
166 ineligible
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that might increase the risk associated with study 
participation or that might have interfered with the 
interpretation of results) or with current or past medical 
history of conditions associated with thrombocytopenia, 
coagulopathy, or platelet dysfunction were excluded. 
Patients with any previous systemic JAK inhibitor use, 
systemic corticosteroid use within 4 weeks of study 
initiation, or treatment with dupilumab within 6 weeks of 
study initiation were also excluded. Patients were 
permitted to use oral anti histamines and topical non­
medicated emollients during the study. Use of topical 
therapies for atopic dermatitis (corticosteroids, cal­
cineurin inhibitors, tars, antibiotic creams, and topical 
antihistamines) and rescue medi cation was not permitted. 
Full inclusion and exclusion criteria are shown in the 
appendix (pp 2–9).
This study was done in accordance with the 
Declaration of Helsinki and International Council for 
Harmonization Good Clinical Practice Guidelines. All 
local regulatory requirements were fol lowed. The study 
protocol was approved by institutional review boards or 
ethics com mittees at each study site. Internal and 
external review committees monitored the safety of 
patients throughout the study. All patients provided 
written informed consent. The study protocol is 
available online.
Randomisation and masking
Patients were randomly assigned (2:2:1) to receive oral 
abrocitinib 100 mg, abrocitinib 200 mg, or matching 
placebo, using a central randomisation scheme provided 
by an interactive response technology system. Ran­
domisation was stratified by baseline disease severity 
(Investigator Global Assessment score 3 or 4) and age 
group (<18 years or ≥18 years). Patients, investigators, 
and the funder of the study were masked to study 
treatment. The placebo tablets were identical to the 
abrocitinib 100 mg tablets in size, colour, shape, and 
odour. Patients were given two bottles, and were 
instructed to take one tablet from each bottle: for the 
100 mg group, one bottle contained placebo and the other 
contained abrocitinib 100 mg tablets; for the 200 mg 
group, both bottles contained abrocitinib 100 mg tablets; 
and for the placebo group, both bottles contained placebo 
tablets.
Procedures
Patients were screened within 28 days of the first dose of 
study drug. Screening consisted of laboratory assessment 
(neutrophil, haemoglobin, platelet, and  lymphocyte 
counts; and creatinine, aspartate aminotransferase or 
alanine aminotransferase, and bilirubin levels); complete 
blood count and blood chemistry, lipid panels, vital 
signs, and electrocardiogram; and hepatitis and 
tuberculosis testing. Chest x­rays were also done as 
appropriate. Patients received oral abrocitinib 100 mg, 
abrocitinib 200 mg, or matching placebo once daily 
for 12 weeks. Follow­up efficacy, safety, and laboratory 
assessments were done at weeks 2, 4, 6, 8, and 12 







Age, years 31·5 (14·4) 32·6 (15·4) 33·0 (17·4)
Age group, years
<18 17 (22%) 34 (22%) 33 (21%)
18–65 59 (77%) 118 (76%) 110 (71%)
≥65 1 (1%) 4 (3%) 11 (7%)
Sex
Men 49 (64%) 90 (58%) 81 (53%)
Women 28 (36%) 66 (42%) 73 (47%)
Race
White 62 (81%) 113 (72%) 104 (68%)
Black or African American 6 (8%) 15 (10%) 11 (7%)
Asian 6 (8%) 26 (17%) 26 (17%)
Other* 2 (3%) 2 (1%) 11 (7%)
Not reported 1 (1%) 0 2 (1%)
Ethnicity
Hispanic or Latino 6 (8%) 10 (6%) 4 (3%)
Not Hispanic or Latino 71 (92%) 144 (92%) 149 (97%)
Not reported 0 2 (1%) 1 (1%)
Disease duration, years 22·5 (14·4) 24·9 (16·1) 22·7 (14·5)
Previous medication for atopic dermatitis†
Any previous medication 77 (100%) 155 (99%) 154 (100%)
Topical drugs alone‡ 34 (44%) 69 (44%) 82 (53%)
Systemic medication with or without 
topical drugs§
41 (53%) 78 (50%) 68 (44%)
Dupilumab 8 (10%) 13 (8%) 9 (6%)
Investigator Global Assessment score
3 (moderate disease) 46 (60%) 92 (59%) 91 (59%)
4 (severe disease) 31 (40%) 64 (41%) 63 (41%)
EASI score 28·7 (12·5) 31·3 (13·6) 30·6 (14·1)
Body surface area affected, % 47·4 (22·7) 50·8 (23·4) 49·9 (24·4)
SCORAD score 64·5 (13·2) 67·1 (13·7) 64·3 (13·1)
PP-NRS score¶ 7·0 (1·8) 6·9 (2·0) 7·1 (1·9)
PSAAD total score|| 5·5 (2·0) 5·3 (2·3) 5·4 (2·1)
DLQI total score** 13·9 (7·3) 14·6 (6·5) 14·6 (6·8)
CDLQI total score†† 13·6 (7·0) 11·7 (6·6) 13·2 (5·5)
POEM total score‡‡ 19·9 (6·1) 19·5 (6·5) 19·6 (5·9)
Data are mean (SD) or n (%). EASI=Eczema Area and Severity Index. SCORAD=SCORing Atopic Dermatitis. PP-NRS=Peak 
Pruritus Numerical Rating Scale. PSAAD= Pruritus and Symptoms Assessment for Atopic Dermatitis. DLQI=Dermatology 
Life Quality Index. CDLQI=Children’s Dermatology Life Quality Index. POEM=Patient Oriented Eczema Measure. 
*Includes patients that were American Indian or Alaskan Native, Native Hawaiian or Pacific Islander, or multiracial. 
†Patients were counted for each main category (ie, topical agents or systemic agents) in an exclusive manner. 
‡Topical agents includes corticosteroids and calcineurin inhibitors. §Systemic agents includes mycophenolate mofetil, 
methotrexate, azathioprine, corticosteroids, ciclosporin, and dupilumab. ¶Data were available for 77 patients in the 
placebo group, 155 patients in the abrocitinib 100 mg group, and 154 patients in the abrocitinib 200 mg group. 
||Data were available for 68 patients in the placebo group, 137 patients in the abrocitinib 100 mg group, and 
138 patients in the abrocitinib 200 mg group. **Assessed in patients aged ≥18 years; data were available for 60 patients 
in the placebo group, 121 patients in the abrocitinb 100 mg group, and 119 patients in the abrocitinb 200 mg group. 
††Assessed in patients aged <18 years; data were available for 16 patients in the placebo group, 32 patients in the 
abrocitinb 100 mg group, and 32 patients in the abrocitinb 200 mg group. ‡‡Data were available for 77 patients in the 
placebo group, 153 patients in the abrocitinib 100 mg group, and 153 patients in the abrocitinib 200 mg group.
Table 1: Demographic and baseline characteristics
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questionnaires.
Outcomes
The coprimary endpoints were the proportion of patients 
who had achieved an Investigator Global Assessment 
response (score of 0 [clear] or 1 [almost clear] and a 
≥2­grade improvement from baseline), and the 
proportion of patients who had achieved at least a 75% 
improvement in EASI score from baseline (EASI­75) at 
week 12 of treatment. Both coprimary endpoints must 
have achieved statistically significant difference from 
placebo to meet the primary objective.
Multiplicity­controlled key secondary endpoints were 
the proportion of patients who achieved a PP­NRS 
response (≥4 point improvement from baseline in PP­NRS 
score) at weeks 2, 4, and 12, and least squares mean 
change from baseline in Pruritus and Symptoms 
Assessment for Atopic Dermatitis (PSAAD; 11­item 
questionnaire developed to measure daily symptoms of 
atopic dermatitis) total score23 at week 12. Other secondary 
endpoints were: the proportion of patients who achieved 
an Investigator Global Assess ment response at all other 
scheduled timepoints (weeks 2, 4, and 8); proportion of 
patients who achieved EASI­75 at all other scheduled 
timepoints (weeks 2, 4, and 8); the proportion of patients 
who achieved EASI­50 (≥50% improvement from 
baseline) and EASI­90 (≥90% improvement from baseline) 
at all scheduled timepoints; the proportion of patients 
who achieved a PP­NRS response at week 8; time from 
baseline to PP­NRS response; and the proportion of 
patients who achieved an improvement of 75% or more in 
SCORing Atopic Dermatitis (SCORAD)24 score from 
baseline at all scheduled timepoints. The other secondary 
endpoints, which will be reported elsewhere, were: the 
proportion of patients who achieved an improvement of 
50% or more in SCORAD score from baseline at all 
scheduled timepoints; change from baseline in percentage 
body surface area affected at all timepoints; and change 
from baseline in SCORAD subjective assessments of itch 
and sleep loss at all scheduled timepoints. Patient­reported 
outcomes were change from baseline in Patient­Oriented 
Eczema Measure (POEM)25 total score and Dermatology 
Life Quality Index (DLQI; assessed in patients aged 
≥18 years)26 or children’s DLQI (CDLQI; assessed in 
patients aged <18 years)27 total score at week 12 and all 
other timepoints. The other patient­reported outcomes, 
which will be reported elsewhere, were: Hospital Anxiety 
and Depression Scale, and Patient Global Assessment, 
EuroQol Quality of Life 5­Dimension 5­Level Scale or 
EuroQol Quality of Life 5­Dimension Youth Scale, 
Functional Assessment of Chronic Illness Therapy 
Fatigue Scale (FACIT­F) or Pediatric FACIT­F, and Short 
Form 36 Health Survey version 2 (SF­36v2) at week 12 
and all other timepoints. Pharmacokinetic analysis will 
also be reported elsewhere.
Adverse events, serious adverse events, and adverse 
events leading to discontinuation from the first dose of 
study drug were assessed over the 12­week treatment 
period until 28 days after the last dose of study drug. The 
incidence of clinical abnormalities, change from baseline 
in clinical laboratory values, electrocardiogram (ECG) 
measurements, and vital signs were also recorded.
Statistical analysis
A sample size of 375 patients (150, 150, and 75 patients 
randomly assigned to [A: I have not added ‘to receive’ 
here because we are talking about the groups] 100 mg, 
200 mg, and placebo groups, respectively) was required 
to provide at least 95% power to detect at least 20% 
difference in Inves tigator Global Assessment response 
rates between either abrocitinib dose and placebo, 
assuming a response rate of 6% in the placebo group at 
week 12, and at least 99% power to detect a difference in 
EASI­75 response rate of at least 30% between either 
abrocitinib dose and placebo, assuming a response rate 
of 15% in the placebo group at week 12. The type­1 error 
for testing each individual coprimary endpoint was set at 
Placebo 
(n=77)
Abrocitinib 100 mg 
(n=156)
Abrocitinib 200 mg 
(n=154)
Coprimary endpoints
Investigator Global Assessment response at 12 weeks
Responders, n/N (%) 6/76 (8%) 37/156 (24%) 67/153 (44%)
Percentage difference compared 
with placebo (95% CI)
·· 15·8 (6·8 to 24·8) 36·0 (26·2 to 45·7)
p value ·· 0·0037 <0·0001
EASI-75 response at 12 weeks
Responders, n/N (%) 9/76 (12%) 62/156 (40%) 96/153 (63%)
Percentage difference compared 
with placebo (95% CI)
·· 27·9 (17·4 to 38·3) 51·0 (40·5 to 61·5)
p value ·· <0·0001 <0·0001
Key secondary endpoints
PP-NRS response*
Responders at week 2, n/N (%) 2/74 (3%) 30/147 (20%) 67/147 (46%)
Percentage difference compared 
with placebo (95% CI)
·· 18·0 (10·2 to 25·8) 42·5 (33·6 to 51·4)
p value ·· 0·0004 <0·0001
Responders at week 4, n/N (%) 13/74 (17%) 47/147 (32%) 86/147 (59%)
Percentage difference compared 
with placebo (95% CI)
·· 15·0 (1·9 to 28·0) 41·1 (27·8 to 54·4)
p value ·· 0·0251 <0·0001
Responders at week 12, n/N (%) 11/74 (15%) 55/147 (38%) 84/147 (57%)
Percentage difference compared 
with placebo (95% CI)
·· 22·5 (10·3 to 34·8) 41·7 (29·6 to 53·9)
p value ·· 0·0003 <0·0001
PSAAD total score change from baseline at week 12
n 68 137 138
Least squares mean change from 
baseline (95% CI)
−1·1 (−1·7 to −0·6) −2·2 (−2·6 to −1·9) −3·2 (−3·6 to −2·8)
Difference in least squares mean 
change compared with placebo 
(95% CI)
– −1·1 (−1·7 to −0·4) −2·1 (−2·7 to −1·4)
p value – 0·0010 <0·0001
(Table 2 continues on next page)
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5%. The coprimary endpoints tested the hypotheses of 
superiority of each abrocitinib dose compared with 
placebo in both Investigator Global Assessment and 
EASI­75 response at week 12 (two hypotheses). The key 
secondary endpoints tested the hypothesis of superiority 
of each abrocitinib dose compared with placebo in 
PP­NRS response at weeks 2, 4, and 12, and the change 
from baseline in PSAAD total score at week 12 
(8 hypotheses). The familywise type­1 error rate for 
testing the coprimary and key secondary endpoints was 
controlled at 5% using a sequential, Bonferroni­based 
procedure. Testing of all other secondary endpoints was 
done at the nominal 5% significance level and was not 
controlled for multiplicity.
The primary analysis population for efficacy data was 
the full analysis set, which included all randomised 
patients who received at least one dose of study 
medication. The coprimary and key secondary endpoints 
were analysed using the Cochran­Mantel­Haenszel test, 
adjusted for randomisation strata (baseline disease 
severity and age group). All other binary endpoints were 
analysed using the same methods. Missing responses 
for patients who permanently discontinued the study 
(including those who discontinued due to use of protocol­
prohibited atopic dermatitis medication, such as topical 
corticosteroids) were defined as non­responders at all 
visits after discontinuation. We also did sensitivity ana­
lyses, in which the coprimary endpoints were analysed 
using the per­protocol analysis set and using a tipping 
point analysis based on the full analysis set. Patients with 
major protocol violations and who had missing responses 
for the coprimary endpoints were excluded from the per­
protocol analysis; the tipping point analysis imputed 
all missing responses using a multiple imputation 
approach. All continuous endpoints were analysed using 
a mixed­effect model with repeated measures (MMRM) 
on the basis of all observed data. The model included 
factors (fixed effects) for treatment group, randomisation 
strata (age group, baseline disease severity), visit, treat­
ment­by­visit interaction, and relevant baseline value. 
Within the framework of MMRM, treatment difference 
was tested at the prespecified primary timepoint (week 12) 
and at the other timepoints (weeks 2, 4, and 8) by time­
point­specific contrasts from the MMRM model. No 
explicit imputations were made for missing data, and 
the MMRM model yields valid inferences under the 
assumption of a missing at random mechanism. Safety 
was assessed in all patients who received study 
medication. All safety data were summarised using 
descriptive statistics. SAS software (version 9.4) was used 
Placebo 
(n=77)
Abrocitinib 100 mg 
(n=156)
Abrocitinib 200 mg 
(n=154)
(Continued from previous page)
Other secondary endpoints
EASI-90 response at week 12
Responders, n/N (%) 4/76 (5%) 29/156 (19%) 59/153 (39%)
Percentage difference compared 
with placebo (95% CI)
·· 13·3 (5·4 to 21·2) 33·4 (24·3 to 42·5)
EASI-50 response at week 12
Responders, n/N (%) 17/76 (22%) 90/156 (58%) 116/153 (76%)
Percentage difference compared 
with placebo (95% CI)
·· 35·3 (23·3 to 47·4) 53·5 (42·0 to 65·0)
PP-NRS response* at week 8
Responders, n/N (%) 11/74 (14%) 50/147 (34%) 88/147 (60%)
Percentage difference compared 
with placebo (95% CI)
·· 20·0 (7·4 to 32·7) 45·3 (32·7 to 57·8)
Change in DLQI total score from baseline at week 12
Patients assessed, n 60 121 119
Least squares mean change from 
baseline (95% CI)
–4·2 (–5·9 to –2·5) –7·0 (–8·1 to –5·8) –9·1 (–10·3 to –8·0)
Least squares mean difference 
compared with placebo (95% CI)
·· –2·8 (–4·8 to –0·8) –4·9 (–6·9 to –2·9)
Change in CDLQI total score from baseline at week 12
Patients assessed, n 16 32 32
Least squares mean change from 
baseline (95% CI)
–3·9 (–6·1 to –1·7) –6·4 (–7·9 to –5·0) –7·5 (–8·9 to –6·0)
Least squares mean difference 
compared with placebo (95% CI)
·· –2·5 (–5·2 to 0·1) –3·6 (–6·2 to –0·9)
Change in POEM total score from baseline at week 12
Patients assessed, n 77 153 153
Least squares mean change from 
baseline (95% CI)
–3·7 (–5·5 to –1·9) –6·8 (–8·0 to –5·6) –10·6 (–11·8 to –9·4)
Least squares mean difference 
compared with placebo (95% CI)
.. –3·1 (–5·2 to –0·9) –6·9 (–9·0 to –4·7)
p values for coprimary and key secondary efficacy endpoints were adjusted for multiplicity. Testing of secondary endpoints 
was not controlled for multiplicity; thus, p values are not provided. For PP-NRS responses, the estimated number of 
responders, response rates, and 95% CIs were obtained from a multiple imputation procedure accounting for any other 
missing data that were not already handled by non-responder imputation. EASI=Eczema Area and Severity Index. 
EASI-75=Improvement of at least 75% in EASI score from baseline. PP-NRS=Peak Pruritus Numeric Rating Scale. 
PSAAD=Pruritus and Symptoms Assessment for Atopic Dermatitis. EASI-90=Improvement of at least 90% in EASI score 
from baseline. EASI-50=Improvement of at least 50% in EASI score from baseline. DLQI=Dermatology Life Quality Index. 
CDLQI= Children’s Dermatology Life Quality Index. POEM=Patient Oriented Eczema Measure. *Defined as a 4-point 
or greater improvement from baseline in PP-NRS score.
Table 2: Summary of efficacy endpoints and 12-week patient-reported outcomes
Figure 2: Proportion of patients who achieved an IGA response over the 
12-week treatment period
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for all statistical analysis. This study is registered with 
ClinicalTrials.gov, NCT03349060.
Role of the funding source
The study was designed, funded, and managed by the 
funder. The funder collected, managed data, and analysed 
data. All authors participated in interpretation of the 
data, preparation, review, and approval of the manuscript 
and decision to submit the manuscript for publication. 
Medical writing and editorial support were provided and 
funded by the funder.
Results 
Between Dec 7, 2017, and March 26, 2019, we screened 
553 patients, of whom 387 were randomly assigned to 
receive abrocitinib 100 mg (n=156), abrocitinib 200 mg 
(n=154), or placebo (n=77). 61 patients in the placebo 
group, 135 patients in the abrocitinib 100 mg group, and 
137 patients in the abrocitinib 200 mg group completed 
the study (figure 1). The most common reason for 
discontinuation of the study in the abrocitinib 100 mg 
and 200 mg groups was adverse events. The proportion 
of patients who discon tinued due to adverse events was 
lower in both abrocitinib groups than in the placebo 
group (figure 1).
Demographics and baseline characteristics were 
balanced across the treatment groups (table 1). Most 
patients in the study were men (57%), with a mean age 
of 32·5 years (SD 16·0). Black (8%) and Asian (15%) 
patients were well represented in the study. The 
proportion of patients with moderate disease (59%) was 
higher than the proportion of patients with severe 
disease (41%), as measured by Investigator Global 
Assessment score. Most patients had received previous 
treatment for atopic dermatitis before the study 
(187 [48%] of 387 patients had received systemic 
medication with or without topical drugs and 185 [48%] 
had received topical drugs alone).
All 156 randomly assigned patients in the abrocitinib 
100 mg group, 154 patients in the abrocitinib 200 mg group 
and 77 patients in the placebo group received at least one 
dose of study drug and thus were included in the full 
analysis set. One patient in the 200 mg abrocitinib group 
and one patient in the placebo group were not assessed for 
the coprimary endpoints at the 12­week timepoint, and 
hence were included in the analysis of the coprimary 
endpoints [A: correct as edited?]. Of the patients with 
available data at week 12 [A: ok?], 37 (24%) of 156 patients 
in the abrocitinib 100 mg group, 67 (44%) of 153 patients in 
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Figure 3: Proportion of patients who achieved an EASI-50 (A), EASI-75 (B), and EASI-90 (C) response over the 12-week treatment period
Error bars show 95% CI. EASI=Eczema Area and Severity Index. EASI-50=Improvement of at least 50% in EASI score from baseline. EASI-75=Improvement of at least 
75% in EASI score from baseline. EASI-90=Improvement of at least 90% in EASI score from baseline.
Figure 4: Proportion of patients who achieved a PP-NRS response* over the 
12-week treatment period
Error bars show 95% CI. PP-NRS=Peak Pruritus Numerical Rating Scale. *Defined 
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the abrocitinib 200 mg group, and six (8%) of 76 patients in 
the placebo group had achieved an Investigator Global 
Assessment response (table 2). The difference in the 
investigator global assessment response rate between the 
placebo and abrocitinib 100 mg group was 15·8% (95% CI 
6·8 to 24·8; p=0·0037) and 36·0% (95% CI 26·2 to 45·7; 
p<0·0001) for the abrocitinib 200 mg group (table 2). Of 
the patients with available data at week 12 [A: ok?], 62 (40%) 
of 156 patients in the abrocitinib 100 mg group, 96 (63%) 
of 153 patients in the abrocitinib 200 mg group, and 
nine (12%) of 76 patients in the placebo group had an 
EASI­75 response (table 2). The difference in EASI­75 
response rate between the placebo group and abrocitinib 
100 mg group was 27·9% (95% CI 17·4 to 38·3; p<0·0001) 
and 51·0% (95% CI 40·5 to 61·5; p<0·0001) for the 
abrocitinib 200 mg group (table 2). Sensitivity analyses 
done for the coprimary endpoints yielded similar results. 
The proportion of patients who had achieved an 
Investigator Global Asses sment and EASI­75 responses at 
12 weeks was higher for both 100 mg and 200 mg 
abrocitinib groups than for the placebo group for 
adolescent and adult patients and patients with moderate 
and severe baseline disease severity (appendix pp 10–11). 
The proportion of patients who had achieved an 
Investigator Global Assessment response was higher in 
the abrocitinib groups than in the placebo group at each 
timepoint, and increased between treatment initiation and 
week 12 (figure 2). The proportion of patients who achieved 
EASI­50, EASI­75, and EASI­90 responses was higher for 
both abrocitinib groups than for the placebo group at each 
timepoint, and increased between treat ment initiation and 
week 12 (table 2; figure 3).
The proportion of patients achieving a PP­NRS 
response increased between week 2 and week 12 for both 
abrocitinib groups, with significant differences identified 
between abrocitinib groups and placebo at weeks 2, 4, 
and 12 (table 2; figure 4). PP­NRS scores decreased 
between baseline and week 12 for both abrocitinib doses 
compared with placebo (figure 5), and this reduction was 
observed within 1 day of the first dose of treatment 
(appendix p 27). The median time to PP­NRS response 
was 84·0 days (IQR 10·0–not evaluable [NE]) in the 
abrocitinib 100 mg group, 14·0 days (6·0–84·0) in the 
abrocitinib 200 mg group, and 92·0 days (29·0–NE) in 
the placebo group (figure 6).
At week 12, the difference in least squares mean 
change from baseline in PSAAD total scores between 
the abrocitinib 100 mg group and the placebo group was 
−1·1 (95% CI −1·7 to −0·4; p=0·0010) and the difference 
between the 200 mg group and the placebo group was 
−2·1 (−2·7 to −1·4; p<0·0001; table 2; appendix p 27). 
The proportion of patients who achieved a SCORAD­75 
response increased between treatment initiation and 
week 12 for both abrocitinib groups. A significant 
difference in SCORAD­75 response rate was identified 
between the abrocitinib 200 mg and the placebo group 
at all timepoints and between the abrocitinib 100 mg 
group and placebo group at weeks 8 and 12 (appendix 
p 28).
At week 12, among adult patients (aged ≥18 years), the 
difference in least squares mean change from baseline 
in DLQI total score was –7·0 (95% CI –8·1 to –5·8) in 
the abrocitinib 100 mg group, –9·1 (–10·3 to –8·0) in 
the abrocitinib 200 mg group, and –4·2 (–5·9 to –2·5) 
in the placebo group (table 2). Reductions in DLQI total 
score were observed between week 2 to 12 for all groups 
Figure 5: Least squares mean change from baseline in PP-NRS score over the 12-week treatment period
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Figure 6: Kaplan-Meier plot of estimated probability of achieving a PP-NRS response*
Plot is based on observed data only (no imputations) and times to event were censored at treatment 
discontinuation, or last observation for patients who had not achieved a response. 23 patients in the placebo 
group, 73 patients in the abrocitinib 100 mg group, and 106 patients in the abrocitinib 200 mg group had 
achieved a response by 16 weeks. PP-NRS=Peak Pruritus Numerical Rating Scale. *Defined as a ≥4-point 
improvement from baseline in PP-NRS score.
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(appendix p 29). At week 12, among adolescent patients 
(aged <18 years), the difference in least squares mean 
change from baseline in CDLQI total score, was –6·4 
(–7·9 to –5·0) in the abrocitinib 100 mg group, 
–7·5 (–8·9 to –6·0) in the abrocitinib 200 mg group, and 
–3·9 (–6·1 to –1·7) in the placebo group (table 2). 
Reductions in CDLQI total score were observed between 
week 2 and 12 for all groups (appendix p 29). For POEM 
total score, the difference in least squares mean change 
from baseline at week 12 was –6·8 (–8·0 to –5·6) for the 
abrocitinib 100 mg group, –10·6 (–11·8 to –9·4) for 
the abrocitinib 200 mg group, and –3·7 (–5·5 to –1·9) for 
the placebo group (table 2). Patients in the abrocitinib 
100 mg and abrocitinib 200 mg groups had significant 
improve ment in POEM score compared with placebo 
between week 2 and 12 (appendix p 30).
Overall, 108 (69%) of 156 patients in the abrocitinib 
100 mg group, 120 (78%) of 154 patients in the abrocitinib 
200 mg group, and 44 (57%) of 77 patients in the placebo 
group reported adverse events (appendix p 13). The 
most frequently reported treatment­emergent adverse 
events in the abrocitinib 100 mg and 200 mg groups 
were nausea and nasopharyngitis; the most frequently 
reported treatment­emergent adverse events in the 
placebo group was dermatitis atopic (table 3). The 
median duration of nausea was 13·0 days (IQR 5·0–NE) 
in the abrocitinib 100 mg group and 39·0 days (4·0–NE) 
in the abrocitinib 200 mg group. The median duration of 
headache was 4·0 days (IQR 1·5–22·0) in the abrocitinib 
100 mg group and 3·0 days (1·0–6·0) in the abrocitinib 
200 mg group. One (1%) of 156 patients in the abrocitinib 
100 mg group discontinued treatment due to nausea, 
with no discontinuations due to this adverse event 
observed in the abrocitinib 200 mg or placebo groups. 
No patients discontinued treatment due to headache.
Serious adverse events were reported in five (3%) of 
156 patients in the abrocitinib 100 mg group, five (3%) 
of 154 patients in the abrocitinib 200 mg group, and 
three (4%) of 77 patients in the placebo group (table 3). 
Among these patients, only two serious adverse events 
were considered treatment­related (table 4): one patient 
in the abrocitinib 200 mg group developed chronic 
inflammatory bowel disease during the treatment period, 
abrocitinib was permanently discontinued, and the 
patient recovered; the other patient was in the abrocitinib 
100 mg group and developed acute pancreatitis during 
the treatment period, abrocitinib was permanently 
discontinued, and the patient recovered. No cases of 
venous thromboembolism, malignancies, major adverse 
cardiovascular events, or deaths were observed (table 3).
A total of nine (6%) of 156 patients in the abrocitinib 
100 mg group, nine (6%) of 154 patients in the 
abrocitinib 200 mg group, and seven (9%) of 77 patients 
in placebo group discontinued treatment due to adverse 
events. The most common adverse events leading to 
treatment discontinuation were atopic dermatitis (four 
[3%] of 156 patients) in the abrocitinib 100 mg group, 
gastrointestinal disorders (three [2%] of 154 patients; 
abdominal pain [n=1], inflammatory bowel disease 
[n=1], and vomiting [n=1]) in the abrocitinib 200 mg 
group, and atopic dermatitis (three [4%] of 77 patients) 
in the placebo group (appendix p 12).
Herpes virus infections were reported in all treatment 
groups. One (1%) of 156 patients in the abrocitinib 100 mg 
group, and three (2%) of 154 patients in the abrocitinib 
200 mg group had herpes simplex infection. Herpes 
zoster infection was reported in one (1%) of 156 patients 
in the abrocitinib 100 mg group and two (1%) of 
154 patients in the abrocitinib 200 mg group. Three (2%) 
of 156 patients in the abrocitinib 100 mg group and 
one (1%) of 154 patients in the abrocitinib 200 mg group 
had oral herpes (table 3). Eczema herpeticum was 
Placebo 
(n=77)
 Abrocitinib 100 mg 
(n=156)
 Abrocitinib 200 mg 
(n=154)
Deaths 0 0 0
Serious adverse events 3 (4%) 5 (3%) 5 (3%)
Most frequently reported treatment-emergent adverse events (≥5% in any treatment group)
Nausea 2 (3%) 14 (9%) 31 (20%)
Nasopharyngitis 8 (10%) 23 (15%) 18 (12%)
Headache 2 (3%) 12 (8%) 15 (10%)
Upper respiratory tract infection 5 (7%) 11 (7%) 11 (7%)
Atopic dermatitis 13 (17%) 22 (14%) 8 (5%)
Treatment-emergent herpes viral infection
Any 0 5 (3%) 4 (3%)
Herpes simplex 0 1 (1%) 3 (2%)
Herpes zoster 0 1 (1%) 2 (1%)
Oral herpes 0 3 (2%) 1 (1%)
Eczema herpeticum 1 (1%) 2 (1%) 0
Data are n (%).
Table 3: Adverse events
Placebo 
(n=77)
Abrocitinib 100 mg 
(n=156)
Abrocitinib 200 mg 
(n=154)
General disorders and administration site 
conditions or condition aggravated
1 (1%) 0 0
Appendicitis 1 (%) 0 0
Meniscal degeneration 1 (1%) 0 0
Atopic dermatitis 1 (1%) 0 0
Appendicitis 0 1 (1%) 0
Dizziness 0 1 (%) 0
Seizure 0 1 (1%) 0
Retinal detachment 0 1 (1%) 0
Acute pancreatitis 0 1 (1%)* 0
Inflammatory bowel disease 0 0 1 (1%)*
Peritonsillitis 0 0 1 (1%)
Dehydration 0 0 1 (1%)
Asthma 0 0 2 (1%)
Data are n (%). *Serious adverse event related to treatment.
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reported in two (1%) of 156 patients in the abrocitinib 
100 mg group and one (1%) of 77 patients in the placebo 
group. Conjunctivitis was reported in four (3%) of 
156 patients in the abrocitinib 100 mg group and four 
(3%) of 154 patients in the abrocitinib 200 mg group; no 
cases were reported in the placebo group (appendix p 17).
Dose­related numeric decreases in median platelet 
count were observed in patients in both abrocitinib 
groups, with a nadir observed at week 4, and a return 
toward baseline values thereafter (appendix p 28). Most 
patients in all treatment groups maintained platelet 
counts within the normal range (appendix p 28). 
One patient in the 200 mg abrocitinib group had a 
decreased platelet count on day 30 of the study, which 
was deemed to be non­serious; the patient discontinued 
treatment because of this adverse event on day 55. The 
patient’s platelet count returned to normal 5 days after 
treatment discontinuation. No patients had significant 
changes in haemoglobin, neutrophil, or lymphocyte 
counts. All other observed changes in clinical laboratory 
values, ECG measurements, and vital signs were not 
deemed to be clinically significant.
Discussion
The results of this phase 3 monotherapy trial showed 
that adolescent and adult patients given abrocitinib 
200 mg or 100 mg once daily for 12 weeks had significant 
improvement in the signs and symptoms of atopic 
dermatitis when compared with placebo. Clinically 
meaningful Investigator Global Assessment and EASI­75 
responses were observed in the abrocitinib groups as 
early as week 2 of treatment and continued to increase 
until week 12. Sensitivity analysis using the per­protocol 
analysis set and a tipping point analysis yielded similar 
results: Investigator Global Assessment and EASI­75 
response rates were higher among the two abrocitinib 
groups than the placebo group, when stratified by age 
and disease severity. A significant, rapid (ie, within 
2 days) reduction in pruritus severity and other atopic 
dermatitis symptoms was also observed between treat­
ment initiation and week 12. Patients in the abrocitinib 
groups had improvements in patient­reported quality of 
life compared with placebo, and both abrocitinib doses 
had a favourable benefit–risk profile. The CIs for the 
primary analysis of differences in Investigator Global 
Assessment and EASI­75 response rates versus placebo 
for the 100 mg and 200 mg abrocitinib groups did not 
overlap, indicating that the 200 mg dose could potentially 
be more effective in patients with moderate­to­severe 
atopic dermatitis. However, the study was not designed 
or powered to compare the abrocitinib 200 mg and 
100 mg doses with one another.
The results of this phase 3 study are consistent with the 
results of a previous phase 2b study of abrocitinib in 
adults with moderate­to­severe atopic dermatitis.19 
However, the phase 2b study did not include patients 
aged younger than 18 years. This phase 3 study included 
adolescent patients, although they only comprised 
20% of the study population. The preliminary efficacy 
results in adolescent and adult patients suggest that the 
applicability of abrocitinib treatment might be extended 
to adolescents. The treatment differences observed 
between both abrocitinib groups and the placebo group 
for the coprimary endpoints were observed by week 2 
and did not seem to have plateaued by the end of the 
treatment period of this study, although it is unknown 
whether more prolonged treatment would have resulted 
in additional responders.
In this 12­week study of patients with moderate­to­
severe atopic dermatitis, both doses of abrocitinib 
seemed to have a positive benefit–risk profile compared 
with placebo. The incidence of serious adverse events 
was low (<4%) in both abrocitinib groups and seemed to 
be comparable to placebo, with most events not deemed 
to be treatment­related. The number of patients who 
discontinued treatment due to treatment­related adverse 
events was low in both abrocitinib groups compared 
with the placebo group. JAK inhibition can potentially 
increase the risk of infections due to the involvement of 
JAKs in signalling pathways that regulate host defence 
and immune response.28 However, the incidence of 
serious infections and herpes virus infec tions was low. 
Additionally, no cases of malignancy were reported in 
this study. Future trials with a longer duration are 
required to provide information about the risk of 
malignancy. Depending on selectivity, JAK inhibition 
can potentially result in changes in blood cell counts, 
which are considered to be related to JAK2 effects on 
haematopoiesis. However, in this study of a selective 
JAK1 inhibitor, no significant changes in haemoglobin, 
neutrophils, or lymphocyte counts were obser ved. 
However, we did observe a slight reduction in platelet 
count that retuned towards baseline levels after the 
nadir at week 4. A similar effect on platelet count was 
observed with abrocitinib treatment in the phase 2b 
study.19 The mechanism that led to changes in platelet 
count is unclear but could be a pharmacological effect of 
the drug that could potentially be mediated by the 
inhibition of JAK1 and downstream inhibition of 
thrombopoietin production.29 No cases of venous 
thromboembolism or major adverse cardiovascular 
events were reported, which have been associated with 
some JAK inhibitors. This 12­week study did not address 
long­term safety.
Comparisons of efficacy and safety results of this 
phase 3 study with studies of other treatments for atopic 
dermatitis are complicated by differences in admin­
istration route, treatment period, efficacy endpoints, and 
patient inclusion criteria. However, the efficacy of 
abrocitinib seems to be at least comparable to dupilumab 
in a broadly similar patient population. Considering that 
response to abrocitinib treatment had not plateaued by 
week 12 of the study, comparisons with the 16­week SOLO 
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Additi onally, previous dupilumab monotherapy studies 
have not included adolescents.
Abrocitinib is a small molecule, thus obviating issues 
potentially arising from subcutaneous injection such as 
injection­site reactions and minimising the possibility of 
development of anti­drug antibodies compared with 
biologic treatments. Additionally, abrocitinib can be 
used by patients who are unwilling to receive injections, 
such as paediatric patients, and might have a potential 
use in patients that only require seasonal or episodic 
treatment or a more flexible dosing regimen adapted to 
individual signs and symptoms. Conjunctivitis is a side­
effect that has been observed in up to 28% of patients in 
previous dupilumab trials;31 however, in our study, 3% of 
participants in the abrocitinib treatment groups reported 
conjunctivitis.
This study was limited by the 12­week treatment period, 
which did not address the long­term efficacy and safety 
of abrocitinib. Additionally, this study did not compare 
the efficacy of abrocitinib versus the current standard of 
care in moderate­to­severe atopic dermatitis. Although 
concomitant topical therapies were not allowed in this 
study, abrocitinib could be used in combination with 
topical therapies in patients with moderate­to­severe 
atopic dermatitis in clinical practice, which was not 
addressed by this study. Several current and future 
phase 3 studies are designed to address these topics 
(NCT03627767, NCT03720470). Furthermore, the study 
was not designed to compare the 200 mg and 100 mg 
abrocitinib doses.
In conclusion, oral abrocitinib 100 mg or 200 mg mono­
therapy given once daily was effective and well tolerated 
in patients with moderate­to­severe atopic dermatitis 
with a favourable benefit­risk profile. Abrocitinib could 
present a promising novel oral systemic drug to treat 
moderate­to­severe atopic dermatitis not controlled by 
topical therapies in patients aged 12 years and older.
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